Search

Your search keyword '"Forconi, Francesco"' showing total 14 results
Start Over Author "Forconi, Francesco" Publisher elsevier bv
14 results on '"Forconi, Francesco"'

1. Activity of venetoclax in patients with relapsed or refractory chronic lymphocytic leukaemia: analysis of the VENICE-1 multicentre, open-label, single-arm, phase 3b trial

Author

Kater, Arnon P, primary, Arslan, Önder, additional, Demirkan, Fatih, additional, Herishanu, Yair, additional, Ferhanoglu, Burhan, additional, Diaz, Marcos Gonzalez, additional, Leber, Brian, additional, Montillo, Marco, additional, Panayiotidis, Panayiotis, additional, Rossi, Davide, additional, Skarbnik, Alan, additional, Tempescul, Adrian, additional, Turgut, Mehmet, additional, Mellink, Clemens H, additional, van der Kevie-Kersemaekers, Anne-Marie F, additional, Lanham, Stuart, additional, Sale, Ben, additional, Del Rio, Luis, additional, Popovic, Relja, additional, Chyla, Brenda J, additional, Busman, Todd, additional, Komlosi, Viktor, additional, Wang, Xifeng, additional, Sail, Kavita, additional, Pena, German E, additional, Vizkelety, Tamas, additional, and Forconi, Francesco, additional

Published
2024
Full Text
View/download PDF

2. Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): interim analysis of a multicentre, open-label, randomised, phase 3 trial

Author

Hillier, Peter R, Pitchford, Alexandra, Bloor, Adrian, Broom, Angus, Young, Moya, Kennedy, Ben M., Walewska, Renata, Furtado, Michelle, Preston, Gavin, Nelson, Jeffrey R, Pemberton, Nicholas, Sidra, Gamal, Morley, Nicholas H., Cwynarski, Kate, Schuh, Anna H., Forconi, Francesco, Elmusharaf, Nagah, Paneesha, Shankara, Fox, Christopher, Howard, Dena R., Hockaday, Anna, Brown, Julia, Cairns, David A., Jackson, Sharon (Shae) Margaret, Greatorex, Natasha, Webster, Nichola, Shingles, Jane, Dalal, Surita, Patten, Piers E.M., Allsup, David, Rawson, Andrew David, and Munir, Talha

Subjects
Oncology
Abstract

Background: the approval of Bruton tyrosine kinase (BTK) inhibitors in patients with previously untreated chronic lymphocytic leukaemia (CLL) was based on trials which compared ibrutinib with alkylating agents in patients considered unfit for fludarabine, cyclophosphamide, and rituximab, the most effective chemoimmunotherapy in CLL. We aimed to assess whether ibrutinib and rituximab is superior to fludarabine, cyclophosphamide, and rituximab in terms of progression-free survival.Methods: this study is an interim analysis of FLAIR, which is an open-label, randomised, controlled, phase 3 trial in patients with previously untreated CLL done at 101 UK National Health Service hospitals. Eligible patients were between 18 and 75 years of age with a WHO performance status of 2 or less and disease status requiring treatment according to International Workshop on CLL criteria. Patients with greater than 20% of their CLL cells having the chromosome 17p deletion were excluded. Patients were randomly assigned (1:1) by means of minimisation (Binet stage, age, sex, and centre) with a random element in a web-based system to ibrutinib and rituximab (ibrutinib administered orally at 420 mg/day for up to 6 years; rituximab administered intravenously at 375 mg/m2 on day 1 of cycle 1 and at 500 mg/m2 on day 1 of cycles 2–6 of a 28-day cycle) or fludarabine, cyclophosphamide, and rituximab (fludarabine 24 mg/m2 per day orally on day 1–5, cyclophosphamide 150 mg/m2 per day orally on days 1–5; rituximab as above for up to 6 cycles). The primary endpoint was progression-free survival, analysed by intention to treat. Safety analysis was per protocol. This study is registered with ISRCTN, ISRCTN01844152, and EudraCT, 2013-001944-76, and recruiting is complete.Findings: between Sept 19, 2014, and July 19, 2018, of 1924 patients assessed for eligibility, 771 were randomly assigned with median age 62 years (IQR 56–67), 565 (73%) were male, 206 (27%) were female and 507 (66%) had a WHO performance status of 0. 385 patients were assigned to fludarabine, cyclophosphamide, and rituximab and 386 patients to ibrutinib and rituximab. After a median follow-up of 53 months (IQR 41–61) and at prespecified interim analysis, median progression-free survival was not reached (NR) with ibrutinib and rituximab and was 67 months (95% CI 63–NR) with fludarabine, cyclophosphamide, and rituximab (hazard ratio 0·44 [95% CI 0·32–0·60]; pInterpretation: front line treatment with ibrutinib and rituximab significantly improved progression-free survival compared with fludarabine, cyclophosphamide, and rituximab but did not improve overall survival. A small number of sudden unexplained or cardiac deaths in the ibrutinib and rituximab group were observed largely among patients with existing hypertension or history of cardiac disorder.

Published
2023

3. Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): interim analysis of a multicentre, open-label, randomised, phase 3 trial

Author

Hillmen, Peter, primary, Pitchford, Alexandra, additional, Bloor, Adrian, additional, Broom, Angus, additional, Young, Moya, additional, Kennedy, Ben, additional, Walewska, Renata, additional, Furtado, Michelle, additional, Preston, Gavin, additional, Neilson, Jeffrey R, additional, Pemberton, Nicholas, additional, Sidra, Gamal, additional, Morley, Nicholas, additional, Cwynarski, Kate, additional, Schuh, Anna, additional, Forconi, Francesco, additional, Elmusharaf, Nagah, additional, Paneesha, Shankara, additional, Fox, Christopher P, additional, Howard, Dena R, additional, Hockaday, Anna, additional, Brown, Julia M, additional, Cairns, David A, additional, Jackson, Sharon, additional, Greatorex, Natasha, additional, Webster, Nichola, additional, Shingles, Jane, additional, Dalal, Surita, additional, Patten, Piers E M, additional, Allsup, David, additional, Rawstron, Andrew, additional, and Munir, Talha, additional

Published
2023
Full Text
View/download PDF

5. B-cell receptor signaling induces proteasomal degradation of PDCD4 via MEK1/2 and mTORC1 in malignant B cells

Author

Taylor, Joe, primary, Wilmore, Sarah, additional, Marriot, Sophie, additional, Rogers-Broadway, Karly-Rai, additional, Fell, Rachel, additional, Minton, Annabel R., additional, Branch, Tom, additional, Ashton-Key, Meg, additional, Coldwell, Mark, additional, Stevenson, Freda K., additional, Forconi, Francesco, additional, Steele, Andrew J., additional, Packham, Graham, additional, and Yeomans, Alison, additional

Published
2022
Full Text
View/download PDF

6. CLL-088: Neutropenia Analysis of Venetoclax Monotherapy in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia: Pooled Data from VENICE-I and -II Phase 3b Trials

Author

Anderson, Mary Ann, primary, Davids, Matthew S., additional, Kater, Arnon P., additional, Cochrane, Tara, additional, Demirkan, Fatih, additional, Herishanu, Yair, additional, Leber, Brian, additional, Nikitin, Eugene, additional, Masud, Abdullah A., additional, Rosenberg, Tanya S., additional, Sharmokh, Simon, additional, Fort, Stan, additional, and Forconi, Francesco, additional

Published
2020
Full Text
View/download PDF

7. Acalabrutinib monotherapy in patients with Waldenström macroglobulinemia: a single-arm, multicentre, phase 2 study

Author

Owen, Roger G, primary, McCarthy, Helen, additional, Rule, Simon, additional, D'Sa, Shirley, additional, Thomas, Sheeba K, additional, Tournilhac, Olivier, additional, Forconi, Francesco, additional, Kersten, Marie José, additional, Zinzani, Pier Luigi, additional, Iyengar, Sunil, additional, Kothari, Jaimal, additional, Minnema, Monique C, additional, Kastritis, Efstathios, additional, Aurran-Schleinitz, Thérèse, additional, Cheson, Bruce D, additional, Walter, Harriet, additional, Greenwald, Daniel, additional, Chen, Dih-Yih, additional, Frigault, Melanie M, additional, Hamdy, Ahmed, additional, Izumi, Raquel, additional, Patel, Priti, additional, Wei, Helen, additional, Lee, Sun Ku, additional, Mittag, Diana, additional, and Furman, Richard R, additional

Published
2020
Full Text
View/download PDF

8. International Prognostic Score (IPS-A) for Patients with Early Stage Chronic Lymphocytic Leukemia

Author

Condoluci, Adalgisa, primary, di Bergamo, Lodovico Terzi, additional, Langerbeins, Petra, additional, Hoechstetter, Manuela, additional, Herling, Carmen, additional, De Paoli, Lorenzo, additional, Delgado, Julio, additional, Rabe, Kari G., additional, Gentile, Massimo, additional, Doubek, Michael, additional, Mauro, Francesca Romana, additional, Chiodin, Giorgia, additional, Mattsson, Mattias, additional, Bahlo, Jasmin, additional, Cutrona, Giovanna, additional, Kotaskova, Jana, additional, Deambrogi, Clara, additional, Spina, Valeria, additional, Bruscaggin, Alessio, additional, Moia, Riccardo, additional, Bianchi, Elena, additional, Gerber, Bernhard, additional, Zucca, Emanuele, additional, Ghielmini, Michele, additional, Cavalli, Franco, additional, Stüssi, Georg, additional, Neri, Antonino, additional, Ferrarini, Manlio, additional, Rosenquist, Richard, additional, Forconi, Francesco, additional, Foà, Robin, additional, Pospisilova, Sarka, additional, Morabito, Fortunato, additional, Parikh, Sameer A., additional, Wierda, William G., additional, Montserrat, Emili, additional, Gaidano, Gianluca, additional, Hallek, Michael, additional, and Rossi, Davide, additional

Published
2019
Full Text
View/download PDF

9. Acalabrutinib in Patients (pts) with Waldenström Macroglobulinemia (WM)

Author

Owen, Roger, primary, McCarthy, Helen, additional, Rule, Simon, additional, D'Sa, Shirley, additional, Thomas, Sheeba, additional, Forconi, Francesco, additional, Anderson, Thomas, additional, Kersten, Marie José, additional, Zinzani, Pier Luigi, additional, Iyengar, Sunil, additional, Kothari, Jaimal, additional, Minnema, Monique, additional, Kastritis, Efstathios, additional, Izumi, Raquel, additional, Slatter, J. Greg, additional, Mittag, Diana, additional, Wei, Helen, additional, Chen, Dih-Yin, additional, Patel, Priti, additional, and Furman, Richard R., additional

Published
2018
Full Text
View/download PDF

10. Mutations of BRAF and BIRC3 Identify a Subgroup of Chronic Lymphocytic Leukemia with Very Poor Prognosis upon FCR Treatment

Author

Moia, Riccardo, primary, Diop, Fary, additional, Favini, Chiara, additional, Spaccarotella, Elisa, additional, De Paoli, Lorenzo, additional, Bruscaggin, Alessio, additional, Spina, Valeria, additional, Cerri, Michaela, additional, Deambrogi, Clara, additional, Kodipad, Ahad Ahmed, additional, Favini, Simone, additional, Sagiraju, Sruthi, additional, Jabangwe, Clive, additional, Mauro, Francesca Romana, additional, Del Giudice, Ilaria, additional, Forconi, Francesco, additional, Cortelezzi, Agostino, additional, Zaja, Francesco, additional, Visco, Carlo, additional, Chiarenza, Annalisa, additional, Rigolin, Gian Matteo, additional, Marasca, Roberto, additional, Coscia, Marta, additional, Perbellini, Omar, additional, Tedeschi, Alessandra, additional, Laurenti, Luca, additional, Motta, Marina, additional, Del Poeta, Giovanni, additional, Cuneo, Antonio, additional, Gattei, Valter, additional, Foà, Robin, additional, Gaidano, Gianluca, additional, and Rossi, Davide, additional

Published
2017
Full Text
View/download PDF

11. The variable regulatory B10 capacity of Chronic Lymphocytic Leukemias associates with B-cell receptor anergy and epigenetic programming

Author

Drennan, Samantha, primary, D’Avola, Annalisa, additional, Gao, Yifang, additional, Chrysostomou, Eleni, additional, Steele, Andrew J., additional, Johnson, Peter W., additional, Williams, Anthony P., additional, Packham, Graham, additional, Stevenson, Freda K., additional, Oakes, Christopher C., additional, and Forconi, Francesco, additional

Published
2015
Full Text
View/download PDF

13. Endothelium-mediated survival of leukemic cells and angiogenesis-related factors are affected by lenalidomide treatment in chronic lymphocytic leukemia

Author

Maffei, Rossana, primary, Fiorcari, Stefania, additional, Bulgarelli, Jenny, additional, Rizzotto, Lara, additional, Martinelli, Silvia, additional, Rigolin, Gian Matteo, additional, Debbia, Giulia, additional, Castelli, Ilaria, additional, Bonacorsi, Goretta, additional, Santachiara, Rita, additional, Forconi, Francesco, additional, Rossi, Davide, additional, Laurenti, Luca, additional, Palumbo, Giuseppe A., additional, Vallisa, Daniele, additional, Cuneo, Antonio, additional, Gaidano, Gianluca, additional, Luppi, Mario, additional, and Marasca, Roberto, additional

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results